Status:
COMPLETED
Safety Study of FP-1039 To Treat Cancer
Lead Sponsor:
Five Prime Therapeutics, Inc.
Collaborating Sponsors:
Parexel
Conditions:
Advanced Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The primary purpose of this study is to evaluate the safety and tolerability of FP-1039, a new biologic treatment for cancer.
Eligibility Criteria
Inclusion
- Subjects with metastatic or locally advanced unresectable solid tumors for which standard curative or supportive measures do not exist or are no longer effective
- Male or female 18 years of age or older
Exclusion
- Presence or history of melanoma
- Primary brain tumor
- Presence or history of glaucoma
Key Trial Info
Start Date :
July 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2011
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT00687505
Start Date
July 1 2008
End Date
June 1 2011
Last Update
December 13 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
2
START (South Texas Accelerated Research Therapeutics)
San Antonio, Texas, United States, 78229